

First patients enrolled for Long-COVID study investigating the efficacy of CBD-dominant medicinal cannabis

- **First patients enrolled for open label clinical trial being undertaken in collaboration with the UK's leading independent scientific drug body Drug Science UK – highlights a major step in commercialisation process**
- **Clinical trial designed to investigate the effectiveness of Bod's CBD-dominant medicinal cannabis product on long-COVID – follows authorisation from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA)**
- **30 clinical trial participants with long-COVID to be enrolled and administered daily doses of Bod's medicinal cannabis product MediCabilis® 5%**
- **More than half of the 236 million people globally who have been diagnosed with COVID-19 since December 2019 are expected to experience long-COVID – highlights a major market opportunity for Bod**
- **Bod's medicinal cannabis products, MediCabilis, are currently prescribed to patients with conditions including chronic pain, anxiety and sleep disorders – many of these are symptoms of long-COVID**
- **Clinical trial allows Bod to build IP, define a clear pathway towards commercialisation and progress potential opportunities in the UK and more broadly which have the ability to increase future sales**

Sydney, Australia – 26 April 2022: Cannabis focused drug development and product innovation company Bod Australia Limited ("Bod" or "the Company") (ASX: BOD) is pleased to advise that it has enrolled first patients for its UK-based open label clinical trial in collaboration with Drug Science UK ('Drug Science') (www.drugscience.co.uk) to explore the effectiveness of Bod's medicinal cannabis product MediCabilis® CBD 5% ('MediCabilis') on symptoms associated with the long term impact of SARS-CoV-2 ('COVID-19'), which is commonly referred to as long-COVID.

First participants of the study are registered patients of the Nimbuscare network of GP groups and practices located across York, UK. Drug Science are continuing to actively enrol eligible participants from within the Nimbuscare GP network, which can be viewed and accessed online using the following link: <https://www.nimbuscare.co.uk/>

Long-COVID is an emerging condition referring to the ongoing or new symptoms that develop in the eight weeks following an initial COVID-19 infection. The condition may include the continuation of COVID-19 symptoms from initial diagnosis, or new symptoms that arise around a month after contracting the disease.

Symptoms of long-COVID include shortness of breath, fatigue, ongoing chest discomfort, loss of concentration, chronic pain, anxiety and insomnia. Many of these are amenable to treatment with cannabis-based medicines, highlighting Bod's significant near-term opportunity.

The study aims to recruit 30 participants over the age of 18 that are suffering from long-COVID. Under a clinical trial setting, each patient will be administered MediCabilis on a daily basis over a six month period and undertake self-reporting assessing common long-COVID symptoms including breathlessness, fatigue, cognition and pain through a dedicated smartphone application. The collective results of the trial will determine the feasibility of Bod's medicinal cannabis product in the treatment of the condition and whether it is effective and safe to use for long COVID condition.

The results from the clinical trial will allow Bod to continue the potential commercialisation of a product which can alleviate symptoms of long-COVID, provide the Company with additional evidence in the use of MediCabilis and assist Bod in progressing potential licencing agreements with large pharmaceutical partners or other corporates for its unique extract.

The clinical trial is being led by Principal Investigator, Dr Elizabeth Iverson and undertaken with the UK's leading independent scientific drug body Drug Science UK (refer ASX announcement: 18 March 2021). Drug Science was founded in 2010 and is the only 100% independent, science-led charity in the UK. It is focused on collaborations with experts in various fields to provide an evidence base to create the foundation for sensible drug laws.

CONTACT

T +61 2 9199 5018 E info@bodaustralia.com bodaustralia.com

On a global scale, it is estimated that more than half of the 236 million people who have been diagnosed with COVID-19 since December 2019 will experience long-COVIDⁱ. Further, the UK's Office of National Statistics ('ONS') found that 2.4% of the UK's population was experiencing self-reported long-COVIDⁱⁱ. This highlights a large and near term market opportunity for the Company, as MediCabilis is already used to alleviate conditions which are common in people suffering from this illness.

CEO Ms Jo Patterson said: *"First patient enrolment is a major milestone for Bod and highlights the commencement of this landmark study. We already have data that supports the use of MediCabilis for the alleviation of a number of long-COVID symptoms and look forward to building this out further so that our medicine can be used for another emerging need state."*

"Long-COVID is a major market and this clinical trial will provide Bod with potential evidence for the use of its CBD-dominant medicinal cannabis product. This allows the Company to commercialise another product for a particular need state, as well as the opportunity to build further IP around our unique extract."

Upon completion of the trial, we will continue to work with Drug Science to progress further research, potential licencing opportunities and the sale of MediCabilis as a defined medicine for use against long-COVID."

This announcement has been approved by the Board of Bod Australia Limited.

-ENDS-

About Bod Australia:

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

ⁱ <https://www.sciencedaily.com/releases/2021/10/211013114112.htm>

ⁱⁱ <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/3march2022>